Logo image
BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
Journal article   Open access   Peer reviewed

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association

Michael J. Vido, Kaitlyn Le, Edward J. Hartsough and Andrew E. Aplin
Cell reports (Cambridge), v 25(6), pp 1501-1510.e3
06 Nov 2018
PMID: 30404005
url
https://doi.org/10.1016/j.celrep.2018.10.049View
Published, Version of Record (VoR) Open

Abstract

Cell Biology Life Sciences & Biomedicine Science & Technology
Expression of aberrantly spliced BRAF V600E isoforms (BRAF V600E Delta Ex) mediates resistance in 13%-30% of melanoma patients progressing on RAF inhibitors. BRAF V600E Delta Ex confers resistance, in part, through enhanced dimerization. Here, we uncoupled BRAF V600E Delta Ex dimerization from maintenance of MEK-ERK1/2 signaling. Furthermore, we show BRAF V600E Delta Ex association with its substrate, MEK, is enhanced and required for RAF inhibitor resistance. RAF inhibitor treatment increased phosphorylation at serine 729 (S729) in BRAF V600E Delta Ex. Mutation of S729 to a non-phosphorylatable residue reduced BRAF V600E Delta Ex-MEK interaction, reduced dimerization or oligomerization, and increased RAF inhibitor sensitivity. Conversely, mutation of the BRAF dimerization domain elicited partial effects on MEK association and RAF inhibitor sensitivity. Our data implicate BRAF S729 in resistance to RAF inhibitor and underscore the importance of substrate association with BRAF V600E Delta Ex. These findings may provide opportunities to target resistance driven by aberrantly spliced forms of BRAF V600E.

Metrics

12 Record Views
38 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Cell Biology
Logo image